Because CHB is a significant risk factor for cirrhosis and hepatocellular carcinoma (HCC), intensive efforts have focused on the development of effective therapeutic strategies that aim for the clearance of HBV as measured by hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), viral DNA, normalization of hepatic function indicated by alanine transaminase (ALT), and slowing the progression of cirrhosis and inflammation in the liver [4]. The gene discussed is GPT; the disease is Cirrhosis.